• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Biovaxys Technology Corp (CSE:BIOV)

    0.0600 UNCHANGED
    Streaming Delayed Price Updated: 3:51 PM EDT, Apr 28, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Biovaxys Technology Corp

    < Previous 1 2 Next >
    BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update
    VANCOUVER, BC, April 28 2026 - TheNewswire - BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB0) (OTCQB: BVAXF) (“BioVaxys” or the “Company”) is providing this bi-weekly update on the status of the... 
    Via TheNewswire.com
    BioVaxys Announces Phase I/II PESCO Trial Abstract Accepted for Presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
    VANCOUVER, BC, April 27th, 2026 – TheNewswire - BioVaxys Technology Corp. (CSE: BIOV OTCQB:BVAXF FRA:5LB0) today announced the acceptance of an abstract related to the PESCO study, an... 
    Via TheNewswire.com
    BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update
    VANCOUVER, BC, March 17, 2026 – TheNewswire - BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (“BioVaxys” or the “Company”) is providing this bi-weekly update on the status of the... 
    Via TheNewswire.com
    BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update
    VANCOUVER, BC, March 31, 2026 – TheNewswire - BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB0) (OTCQB: BVAXF) (“BioVaxys” or the “Company”) is providing this bi-weekly update on the status of the... 
    Via TheNewswire.com
    BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update
    VANCOUVER, BC, March 17, 2026 – TheNewswire - BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (“BioVaxys” or the “Company”) is providing this bi-weekly update on the status of the... 
    Via TheNewswire.com
    News headline image
    BioVaxys and AI-Guided mRNA Immunotherapy Leader Adiverna Enter Collaboration to Develop Companion Animals Vaccines
     
    Via TheNewswire.com
    Topics Artificial Intelligence
    News headline image
    BioVaxys Announces Application for Management Cease Trade Order
    Vancouver, BC – TheNewswire - March 3rd, 2026 – BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB) (OTCQB: BVAXF) (“BioVaxys” or the “Company”) announces that it was unable to file its annual financial... 
    Via TheNewswire.com
    News headline image
    BioVaxys Reports Positive Phase 2 Data for Maveropepimut (MVP-S) + Pembrolizumab and Low-Dose Cyclophosphamide in Metastatic Bladder Cancer
    Reinforces Synergistic Potential and Expands Opportunity Beyond Ovarian Cancer 
    Via TheNewswire.com
    News headline image
    BioVaxys 1Q2026 R&D and Collaborative Activity
    Via TheNewswire.com
    News headline image
    2025 Corporate Review
    Via TheNewswire.com
    News headline image
    BioVaxys Announces Positive Phase 1 Clinical Study Results with Maveropepimut-S (MVP-S) in Women with Hormone Receptor Positive/HER2 Negative (HR+/HER2-) Stage II-III Breast Cancer
    Vancouver, British Columbia--(Newsfile Corp. - December 17, 2025) - BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB) (OTCQB: BVAXF) ("BioVaxys" or... 
    Via Newsfile
    News headline image
    BioVaxys Strengthens Scientific Team with Addition of Former IMV Vice President of R&D
    Via TheNewswire.com
    Topics Intellectual Property
    News headline image
    BioVaxys Technology Corp. Closes Debt Settlement Transaction
    Via TheNewswire.com
    News headline image
    BioVaxys Technology Corp. Closes Listed Issuer Financing Exemption (LIFE) Private Placement
    Via TheNewswire.com
    Topics Intellectual Property
    InvestorNewsBreaks – BioVaxys Technology Corp. (CSE: BIOV) (OTCQB: BVAXF) (FRA: 5LB), SpayVac-for-Wildlife Inc. Expand License Agreement
    Via Investor Brand Network
    News headline image
    Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing
    Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
    From Virtual Investor Conferences
    Via GlobeNewswire
    News headline image
    BioVaxys Technology Corp. to Present at the Life Sciences Investor Forum September 19th 2024
    BioVaxys invites individual and institutional investors, as well as advisors and analysts, to attend online at www.VirtualInvestorConferences.com 
    From Virtual Investor Conferences
    Via GlobeNewswire
    News headline image
    Life Sciences Virtual Investor Forum Agenda Announced for September 19th
    Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
    From Virtual Investor Conferences
    Via GlobeNewswire
    News headline image
    The Power Play by The Market Herald Releases New Interviews with Reunion Gold Corp, Numinus Wellness, Core Assets, Blockmate Ventures, BioVaxys Tech, Carlyle Commodities and Belmont Resources Discussing Their Latest News
    Via ACCESSWIRE
    News headline image
    The Power Play by The Market Herald Releases New Interviews with Spey Resources, Melkior Resources and BioVaxys Technology Discussing Their Latest News
    Via ACCESSWIRE
    News headline image
    The Power Play by The Market Herald Releases New Interviews with ApartmentLove, Sirios Resources, Aton Resources, Mountain Boy Minerals and BioVaxys Technology Discussing Their Latest News
    Via ACCESSWIRE
    BioVaxys Announces Successful Test-Run Production of its Bi-Haptenized Ovarian Cancer Vaccine
    Vancouver, BC – December 1, 2022 – BioVaxys Technology Corp. (OTCQB: BVAXF) (CSE: BIOV) (FRA: 5LB) (“BioVaxys” or “Company”) is pleased to announce the successful sterile and bacteria-free test-run... 
    Via FinancialNewsMedia
    Research and Development of Advanced Therapeutics for Ovarian Cancer Fueling Hope
    EQNX::TICKER_START (OTCQB:BVAXF),(NASDAQ:CTIC),(NASDAQ:SGEN),(NYSE:MRK),(NASDAQ:IMGN) EQNX::TICKER_END 
    Via FinancialNewsMedia
    Topics Intellectual Property
    News headline image
    The Power Play by The Market Herald Releases New Interviews with RDARS, Infinity Stone Ventures, BioVaxys Technology, and Sitka Gold Discussing Their Latest News
    Via ACCESSWIRE
    Global Cervical Cancer Treatment Market Size Expected to Reach $11 Billion By 2027
    Palm Beach, FL – October 6, 2022 – FinancialNewsMedia.com News Commentary – The global Cervical Cancer Treatment market has been expanding for several years and is projected to continue at a growing... 
    Via FinancialNewsMedia
    News headline image
    BioVaxys Executes Binding Term Sheet for the US Marketing & Distribution for Papilocare Gel and Oral Immunocaps
    Agreement Includes Right of First Refusal in the US for Ovosicare and Libicare Vancourver, BC – October 6, 2022 – BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (“BioVaxys” or... 
    Via FinancialNewsMedia
    News headline image
    The Power Play by The Market Herald Releases a New Interview with BioVaxys Technology Discussing Their Latest News
    Via ACCESSWIRE
    Advanced Clinical Trials Focus on Development of Vaccines to Prevent Ovarian Cancer Progression
    Palm Beach, FL – May 18, 2022 – FinancialNewsMedia.com News Commentary – Companies in the Ovarian Cancer market are spending a lot of R&D on vaccine development, therapies and studies. For the past 30... 
    Via FinancialNewsMedia
    Topics Death
    BioVaxys Confirms First Clinical Site and Principal Investigators for Ovarian Cancer Vaccine Trial and Enters into Second Tumor Cell Supply Agreement
    Vancouver, BC – May 18, 2022 — BioVaxys Technology Corp. (OTCQB: BVAXF) (CSE: BIOV) (FRA: 5LB) (“BioVaxys” or “Company”), announced today that Hospices Civils de Lyon, France (“HCL”) has agreed to... 
    Via FinancialNewsMedia
    News headline image
    Advanced Immunological and Clinical Trials for Treating Ovarian Cancer Accelerating
    Palm Beach, FL – April 25, 2022 – FinancialNewsMedia.com News Commentary – The formation of mutational cells or tissues in female reproductive organs called ovaries leads to ovarian cancer. Cancer... 
    Via FinancialNewsMedia
    Topics Intellectual Property
    < Previous 1 2 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.